
News|Articles|August 14, 2025
Early Experience of Aflibercept 8mg (EYLEA® 8mg) in Routine Clinical Practice
Advertisement
Sponsored Supplement:
One-to-one interviews with three leading retina specialists from Switzerland, United Kingdom and United States on their early experience of aflibercept 8mg (EYLEA® 8mg) in clinical practice, capturing contemporary insights on treatment strategies and real-world outcomes in patients with neovascular age-related macular degeneration and diabetic macular edema.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
IGS 2026: Navigating MIGS and other modern glaucoma procedures
2
IGS 2026: The expanding role of artificial intelligence in ophthalmology
3
IGS 2026: Considering OCT in neuro-ophthalmology and neurological diseases
4
IGS 2026: Population-based normative data could transform AI in glaucoma
5




























